Genus plc

LSE:GNS Stock Report

Market Cap: UK£1.6b

Genus Future Growth

Future criteria checks 0/6

Genus's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 3.3% per year. EPS is expected to decline by 0.6% per annum. Return on equity is forecast to be 9.9% in 3 years.

Key information

-2.7%

Earnings growth rate

-0.62%

EPS growth rate

Biotechs earnings growth12.2%
Revenue growth rate3.3%
Future return on equity9.88%
Analyst coverage

Good

Last updated30 Apr 2026

Recent future growth updates

Recent updates

GNS: Gene Editing Breakthrough And China JV Will Drive Medium Term Upside

Analysts have lifted their fair value estimate for Genus from £35.00 to £37.00, citing updated assumptions on discount rates, growth, margins, and future P/E multiples reflected in recent Street research, including the £1.00 price target increase reported by Berenberg. Analyst Commentary Recent Street research on Genus points to a more constructive tone on the shares, with bullish analysts reflecting this in higher price targets and refreshed valuation work.

GNS: Gene Editing Progress And China JV Execution Will Shape Medium-Term Upside

Analysts have raised their price target for Genus by £1.00, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E as the key drivers behind the change. Analyst Commentary Bearish analysts view the higher price target and updated assumptions as leaving limited room for error.

GNS: China JV And Gene Editing Progress Will Drive Medium Term Upside

Analysts have nudged their price target on Genus up by £1.00, citing updated fair value and discount rate assumptions along with revised expectations for revenue growth, profit margins and future P/E as the key drivers for the change. Analyst Commentary Bullish Takeaways Bullish analysts see the £1.00 uplift in the price target as aligned with updated fair value work, suggesting that their revised assumptions on revenue growth and margins still support the current valuation framework.

GNS: China JV And Gene Editing Progress Will Support Medium Term Upside

Analysts have raised their price target on Genus by £1.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Analysts lifting their fair value assumptions for Genus are signalling a shift in how they view the balance between the company’s growth potential and execution risks.

GNS: Gene Editing Execution And Regulatory Timelines Will Constrain Medium-Term Upside

Analysts have raised their fair value estimate for Genus from £24.00 to £25.50, reflecting updated assumptions on revenue growth, profit margins and the potential of its gene editing technology as highlighted in recent research. Analyst Commentary Recent street research on Genus highlights a mix of optimism around its gene editing platform and caution around how that potential is reflected in the share price.

GNS: Gene Editing Progress And China JV Will Shape Balanced Medium Term Outlook

Genus's updated analyst price target reflects a modest uplift in estimated fair value to £30.82, supported by higher assumed revenue growth and a richer future P/E multiple, even as analysts factor in a slightly higher discount rate and softer profit margins. Analyst Commentary Recent Street research on Genus points to a generally constructive stance, with analysts revisiting their models and price targets as they reassess the company’s growth potential and execution risks.

GNS: Gene Editing Breakthrough Will Drive Medium Term Upside Potential

Narrative Update on Genus Analysts have lifted their price target on Genus to £31.00 from £29.00, citing the company's gene editing technology and its perceived medium term upside potential as key reasons for the change. Analyst Commentary Bullish analysts are highlighting Genus as a name with medium term upside potential, underpinned by its gene editing capabilities and recent supportive price target work.

GNS: Gene Editing Potential Will Drive Balanced Medium-Term Opportunity And Execution Risk

Narrative Update Analysts now see Genus as fairly valued in a range of £30.50 to £31.00. This reflects a modestly revised P/E assumption, slightly higher revenue growth and profit margin expectations, and a growing focus on the potential of its gene editing technology for medium term upside.

Calculating The Fair Value Of Genus plc (LON:GNS)

Jan 06
Calculating The Fair Value Of Genus plc (LON:GNS)

GNS: Gene Editing Platform Will Shape Balanced Medium-Term Upside And Execution Risks

Genus's analyst price target has been raised from about £18.80 to £24.00 per share as analysts highlight the upside from its gene editing platform and reaffirm Buy ratings alongside recent target hikes from major banks. Analyst Commentary Recent research updates underscore a constructive stance on Genus, with buy ratings supported by the view that its gene editing platform could materially expand medium term earnings power.

GNS: Gene Editing Platform Will Drive Medium Term Upside Despite Execution Risks

Analysts have nudged their price target on Genus higher to £31.00 from £29.00, citing increasing confidence in the medium term upside from its gene editing platform and a modest uplift in expected profitability, even as growth assumptions normalize slightly. Analyst Commentary Bullish analysts highlight that the uplift in price targets reflects growing conviction that Genus can translate its gene editing capabilities into sustained, above-market earnings growth over the medium term.

GNS: Future China Joint Venture Will Improve Near-Term Shareholder Returns

Analysts have increased their price target for Genus from £29.00 to £31.00. This reflects greater confidence in the company's outlook despite moderating growth forecasts and a slightly higher discount rate.

Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price

Nov 15
Benign Growth For Genus plc (LON:GNS) Underpins Its Share Price

Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

Oct 28
Genus (LON:GNS) Is Paying Out A Dividend Of £0.217

We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit

Oct 18
We Like Genus' (LON:GNS) Earnings For More Than Just Statutory Profit

Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

Oct 11
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream

The upward revision in Genus’s price target reflects improved analyst expectations, driven by notable increases in both forecast revenue growth (from 4.0% to 4.9% per annum) and net profit margin (from 7.88% to 8.73%), resulting in a new fair value of £27.97. What's in the News Genus and Beijing Capital Agribusiness Co. (BCA) have accelerated the formation of a Chinese joint venture to commercialise PRRS 2 Resistant Pig (PRP), with BCA holding 51% and Genus 49%.

Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

Sep 07
Genus (LON:GNS) Is Due To Pay A Dividend Of £0.217

There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Jul 25
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Estimating The Fair Value Of Genus plc (LON:GNS)

Jul 22
Estimating The Fair Value Of Genus plc (LON:GNS)

Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry

May 10
Genus plc (LON:GNS) Stock Catapults 36% Though Its Price And Business Still Lag The Industry

An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued

Apr 18
An Intrinsic Calculation For Genus plc (LON:GNS) Suggests It's 21% Undervalued
User avatar

Regulatory Approvals And Sustainability Initiatives Will Strengthen Future Market Position

Expansion in the porcine business and PRRS resistant pig commercialization boosts revenue stability and growth through innovation and market penetration.

There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Feb 01
There's No Escaping Genus plc's (LON:GNS) Muted Revenues Despite A 25% Share Price Rise

Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S

Nov 20
Lacklustre Performance Is Driving Genus plc's (LON:GNS) Low P/S

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

Oct 23
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217

There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Oct 22
There May Be Some Bright Spots In Genus' (LON:GNS) Earnings

Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next

Sep 08
Genus plc Just Missed EPS By 72%: Here's What Analysts Think Will Happen Next

The Price Is Right For Genus plc (LON:GNS)

Jun 16
The Price Is Right For Genus plc (LON:GNS)

Estimating The Fair Value Of Genus plc (LON:GNS)

Apr 20
Estimating The Fair Value Of Genus plc (LON:GNS)

Is Genus (LON:GNS) Using Too Much Debt?

Mar 25
Is Genus (LON:GNS) Using Too Much Debt?

With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Mar 05
With A 26% Price Drop For Genus plc (LON:GNS) You'll Still Get What You Pay For

Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

Feb 25
Genus (LON:GNS) Has Affirmed Its Dividend Of £0.103

Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Jan 17
Getting In Cheap On Genus plc (LON:GNS) Might Be Difficult

Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

Dec 10
Does This Valuation Of Genus plc (LON:GNS) Imply Investors Are Overpaying?

We Think Genus (LON:GNS) Is Taking Some Risk With Its Debt

Nov 03
We Think Genus (LON:GNS) Is Taking Some Risk With Its Debt

Earnings and Revenue Growth Forecasts

LSE:GNS - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202871165721098
6/30/2027696586510111
6/30/2026680126578611
12/31/2025672484664N/A
9/30/2025672334766N/A
6/30/2025673194967N/A
3/31/202567284058N/A
12/31/2024672-43149N/A
9/30/202467021840N/A
6/30/20246698530N/A
3/31/202467121837N/A
12/31/2023673331045N/A
9/30/2023681331348N/A
6/30/2023690331550N/A
3/31/202367634-142N/A
12/31/202266234-1835N/A
9/30/202262838-2534N/A
6/30/202259341-3134N/A
3/31/202258239-2039N/A
12/31/202157037-943N/A
9/30/2021572421355N/A
6/30/2021574473468N/A
3/31/2021570454270N/A
12/31/2020566425072N/A
9/30/2020559394066N/A
6/30/2020551353060N/A
3/31/2020536372555N/A
12/31/2019520391949N/A
9/30/201950423N/A41N/A
6/30/20194898N/A33N/A
3/31/20194801N/A35N/A
12/31/2018471-7N/A37N/A
9/30/201847018N/A40N/A
6/30/201847043N/A43N/A
3/31/201847355N/A42N/A
12/31/201747667N/A41N/A
9/30/201746750N/A38N/A
6/30/201745933N/A35N/A
3/31/201744140N/A34N/A
12/31/201642247N/A33N/A
9/30/201640548N/A31N/A
6/30/201638849N/A30N/A
3/31/201638840N/A25N/A
12/31/201538831N/A21N/A
9/30/201539335N/A28N/A
6/30/201539940N/A35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GNS's earnings are forecast to decline over the next 3 years (-2.7% per year).

Earnings vs Market: GNS's earnings are forecast to decline over the next 3 years (-2.7% per year).

High Growth Earnings: GNS's earnings are forecast to decline over the next 3 years.

Revenue vs Market: GNS's revenue (3.3% per year) is forecast to grow slower than the UK market (4.4% per year).

High Growth Revenue: GNS's revenue (3.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GNS's Return on Equity is forecast to be low in 3 years time (9.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/30 07:32
End of Day Share Price 2026/04/30 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genus plc is covered by 17 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert ChantryBerenberg
Matthew LloydBNP Paribas
Alexander JonesBofA Global Research